Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences

The current standard of care for locally advanced esophageal and gastroesophageal junction cancer is neoadjuvant therapy, yet controversy remains regarding whether chemotherapy or chemoradiation should be the treatment of choice. The literature is broad and contains conflicting reports. We seek to explore factors that impact our selection of one treatment versus the other.